Lumenis' High Speed LightSheer(R) Duet(TM) Featured on ABC's Good Morning America Health as the New Gold Standard for Laser Hair Removal

Recommended for Fast & Comfortable Treatment with Low Risk & High Value

SANTA CLARA, Calif., June 25 /PRNewswire/ -- Lumenis' High Speed LightSheer(R) Duet(TM) for permanent hair reduction was featured yesterday on ABC's Good Morning America Health with Dr. Doris Day, a leading U.S. Dermatologist. During the broadcast, Dr. Day described the LightSheer Duet as 'exciting' and 'the new Gold Standard for laser hair removal,' which she recommends to patients seeking a fast and comfortable treatment with low risk and high value.

Dr. Day added, "I recommend the LightSheer Duet to my patients because it's fast, it's virtually pain-free, and it's permanent. The really great part is that because it's so fast and efficient, the cost per procedure has actually gone down, making laser hair removal more affordable for more of my patients."

"Five years of research led to the development of Lumenis' LightSheer Duet, which offers a high value hair removal solution with unprecedented speed and comfort that benefits both physicians and patients. These benefits have resulted in a very high demand for this exciting new product, in spite of current challenging economic conditions. Clinicians using the new LightSheer Duet report this system reduces hair removal treatment times up to 75% and vastly improves patient comfort, essentially eliminating the need for topical anesthetics and messy treatment gels. These benefits significantly improve practitioner and patient acceptance of hair removal, as well as increase the revenue potential for physician practices and clinics," stated Robert Mann, General Manager of Lumenis' Global Aesthetics & Dermatology Business.

"We are delighted that our LightSheer Duet is experiencing such a positive response to its initial release," commented Mr. Dov Ofer, Lumenis' Chief Executive Officer. "The significant excitement and demand being generated from the LightSheer Duet suggests that we are successfully delivering to the market groundbreaking products that our customers and their patients want and need - which is ultimately our #1 goal," Ofer added.

To watch the Good Morning America Health segment with Dr. Doris Day discussing this exciting new treatment alternative and why she prefers LightSheer Duet over older hair removal methods, go to: http://www.aesthetic.lumenis.com/wt/page/inthenews

About Lumenis' LightSheer Duet

The LightSheer Duet features two hair removal systems on one versatile platform enabling clinicians to optimize permanent hair reduction anywhere on the body. The platform also includes the LightSheer ET system, which is ideal for smaller or bony areas such as the upper lip, chin, or around the ankles. The performance of this system is well documented and clinically validated, satisfying customers worldwide with over 6000 LightSheer systems installed.

The New LightSheer HS (High Speed handpiece) features a large 22x35 mm diode array that is designed for treating large areas such as legs, arms, chests, abdomen, shoulders and backs. LightSheer HS employs fully integrated vacuum assist technology to gently lift skin into the treatment aperture prior to applying laser energy. With this approach, the targeted tissue is gently stretched and thinned, minimizing competing chromophores by blanching vessels and spreading skin pigmentation over a larger area, in addition to pulling the hair follicle closer to the skin's surface. The cumulative result is that energy is delivered more efficiently to achieve excellent clinical results with speed and comfort. These combined features allow clinicians to treat large areas easily and quickly, leading to a significant reduction in treatment time, which essentially eliminates clinician fatigue and revolutionizes treatment economics.

About Lumenis

Lumenis Ltd., a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for aesthetic, surgical and ophthalmic applications, is Israel's largest medical device company with more than 800 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over 100 countries, and an installed base of over 70,000 systems. For more information about Lumenis and its products, log onto www.lumenis.com.

    Lumenis Contact:
    Michelle Maydan
    Director of Corporate Communications
    1-866-569-0597
    +972-4-959-9004
    e-mail: mmaydan@lumenis.com

Lumenis(R) is a registered trademark of Lumenis Ltd.

Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled "Risk Factors", as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.

SOURCE Lumenis Ltd.

RELATED LINKS
http://www.lumenis.com/wt/home/home/?flash=true